Incyte Completes Synteni Acquisition, Begins to Integrate Product Lines | GenomeWeb

PALO ALTO, Calif.--Incyte Pharmaceuticals has completed its acquisition of the gene expression microarray company Synteni that was announced in December. The transaction involves Incyte's issuing shares of its common stock in exchange for all of Synteni's outstanding equity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.